

PCT #3

PATENT
4501-1016

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

CAMPBELL et al.

Conf. 9620

Application No. 10/530,209✓

Group 1615

Filed April 4, 2005

THERAPEUTIC USES OF -CASEIN A² AND DIETARY SUPPLEMENT
CONTAINING CASEIN A²INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with Rules 1.97 and 1.98, and in fulfillment of the duty of disclosure under Rule 1.56, the cited documents are made of record on the enclosed PTO Form-1449.

As the USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and patent publication for applications filed after June 30, 2003, copies of the cited U.S. references are not enclosed, as the present application is filed after June 30, 2003. Copies of the cited foreign patent documents and/or non-patent literature are enclosed.

A concise explanation of the relevance of these items is that these references were cited by the International Patent Office in the corresponding International Application

Docket No. 4501-1016
Appln. No. 10/530,209

Serial No. PCT/NZ2003/000222. A copy of the International Search Report in which they were cited is attached hereto.

Respectfully submitted,

YOUNG & THOMPSON

A handwritten signature in black ink, appearing to read 'Robert J. Patch', written over a horizontal line.

Robert J. Patch, Reg. No. 17,355
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

RJP/psf
July 5, 2005

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Attorney Docket No.:

4501-1016

Application No.:

10/530,209

Applicant:

CAMPBELL et al.

Filing Date:

April 4, 2005

Group Art Unit:

1615

1111 05 2005

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Jim Mann and Murray Skeaff, "β-casein variants and atherosclerosis – claims are premature", <i>Atherosclerosis</i> , Vol. 170, No. 1, September 2003, pp. 11-12
		Tailford et al. "A casein variant in cow's milk is atherogenic", <i>Atherosclerosis</i> , Vol. 170, No. 1, September 2003, pp. 13-19
		Beales et al. "A multi-centre, blinded international trial of the effect of A1 and A2 β-casein variants on diabetes incidence in two rodent models of spontaneous Type I diabetes", <i>Diabetologia</i> , Vol. 45, No. 9, September 2002, pp. 1240-1246
		McLachlan C.N.S. "β-casein A ¹ , ischaemic heart disease mortality, and other illnesses", <i>Medical Hypotheses</i> , Vol. 56, No. 2, February 2001, pp. 262-272

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.